A recent study showed that the administration of GLP-1R agonist in mice with dehydroepiandrosterone-induced PCOS resulted in reduction of hyperinsulinemia and hyperandrogenemia (Zhang et al. 2023a,b). This evidence concerns the gene GLP1R and polycystic ovary syndrome.